Seres Therapeutics Files 8-K with Financial Updates
Ticker: MCRB · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, leases, warrants
TL;DR
Seres Therapeutics filed an 8-K on 8/15/24 with lease details and warrant info.
AI Summary
On August 15, 2024, Seres Therapeutics, Inc. filed an 8-K report detailing financial statements and exhibits. The filing includes information related to lease agreements, including renewal options that can extend leases from approximately one to ten years. It also references warrants and agreements related to Bacthera.
Why It Matters
This filing provides investors with updated financial information and details on lease terms and other agreements, which are crucial for understanding the company's operational commitments and potential future liabilities.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 1-10 years — Lease Renewal Terms (Options can extend lease terms significantly.)
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Filer
- 200 SIDNEY STREET, CAMBRIDGE, MA 02139 (location) — Business and Mail Address
- 20240815 (date) — Filing Date
- Bacthera (company) — Mentioned in agreement context
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to disclose financial statements and exhibits, as well as provide information related to Regulation FD.
What are the potential renewal terms for Seres Therapeutics' leases?
Certain leases include options to renew, exercisable at the Company's sole discretion, with renewal terms that can extend the lease from approximately one year to ten years.
When was Seres Therapeutics, Inc. formerly known as Seres Health, Inc.?
The company's name changed from Seres Health, Inc. to Seres Therapeutics, Inc. on June 3, 2014.
What is the standard industrial classification for Seres Therapeutics, Inc.?
The Standard Industrial Classification for Seres Therapeutics, Inc. is Pharmaceutical Preparations [2834].
What specific agreements are mentioned in relation to the company's financial disclosures?
The filing references agreements related to 'Bacthera' and 'WarrantMember', indicating ongoing business relationships and financial instruments.
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-15 06:05:51
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MCRB Nasdaq Global Select
Filing Documents
- ny20030749x9_8k.htm (8-K) — 204KB
- ny20030749x9_ex99-1.htm (EX-99.1) — 1339KB
- 0001140361-24-037388.txt ( ) — 11073KB
- mcrb-20240815.xsd (EX-101.SCH) — 107KB
- mcrb-20240815_cal.xml (EX-101.CAL) — 89KB
- mcrb-20240815_def.xml (EX-101.DEF) — 499KB
- mcrb-20240815_lab.xml (EX-101.LAB) — 1390KB
- mcrb-20240815_pre.xml (EX-101.PRE) — 741KB
- ny20030749x9_8k_htm.xml (XML) — 1690KB
01
Item 7.01. Regulation FD Disclosure Seres Therapeutics, Inc. (" Seres " or the " Company ") is filing this Current Report on Form 8-K to furnish its historical consolidated financial statements and the notes thereto previously included in its Annual Report on Form 10-K for the fiscal years ended December 31, 2023 and 2022 (the " Prior 10-K ") filed with the Securities and Exchange Commission on March 5, 2024 (such financial statements and notes thereto, the " 2022-2023 Financial Statements "). The 2022-2023 Financial Statements, furnished as Exhibit 99.1 to this Current Report, are consistent in all respects with the financial statements for such periods included in the Prior 10-K. This Current Report does not reflect events occurring after March 5, 2024, the filing date of the Prior 10-K, and does not modify or update the disclosures set forth in the Prior 10-K in any way. Seres expects to incorporate by reference the 2022-2023 Financial Statements in its proxy
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibits Exhibit No. Description 99.1 The audited consolidated financial statements of Seres Therapeutics, Inc., and its subsidiaries as of and for the fiscal years ended December 31, 2023 and 2022, including the consolidated balance sheets and the related consolidated statements of operations and comprehensive loss, of stockholders' equity and of cash flows, and the related notes. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERES THERAPEUTICS, INC. Date: August 15, 2024 By: /s/ Eric D. Shaff Name: Eric D. Shaff Title: President and Chief Executive Officer 2